Teresa Peluso

Bristol-Myers Squibb (Switzerland) — Switzerland

Medicine · Health Sciences

12h-index1.0kcitations64works4.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(54), Protein Degradation and Inhibitors(40), Cancer Treatment and Pharmacology(14), Peptidase Inhibition and Analysis(14), Histone Deacetylase Inhibitors Research(7)

Publications64 total

Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the <scp>OPTIMISMM</scp> Trial
European Journal Of Haematology·2025· 4 citedOpen Access
Brain Abnormalities in Young Single- and Double-Heterozygote Mice for Both Nkx2-1- and Pax8-Null Mutations
Molecular Neurobiology·2024· 1 citedOpen Access
Brain abnormalities in young mice harboring combined NKX2-1 and PAX8 gene mutations
Endocrine Abstracts·2024
Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma
Cell Reports Medicine·2024· 12 citedOpen Access
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival
Frontiers in Oncology·2023· 7 citedOpen Access
OA-44 Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial
Clinical Lymphoma Myeloma & Leukemia·2023· 3 cited
MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
Clinical Lymphoma Myeloma & Leukemia·2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
New England Journal of Medicine·2023· 69 citedOpen Access
POSTER: MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
Clinical Lymphoma Myeloma & Leukemia·2023
P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL
HemaSphere·2023Open Access
Chronic Exposure to Chlorpyrifos Damages Thyroid Activity and Imbalances Hepatic Thyroid Hormones Signaling and Glucose Metabolism: Dependency of T3-FOXO1 Axis by Hyperglycemia
International Journal of Molecular Sciences·2023· 9 citedOpen Access
Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
Blood·2022· 26 cited
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
The Lancet Haematology·2022· 84 cited
Model‐based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma
British Journal of Clinical Pharmacology·2022· 8 cited
P-231: Biomarker analysis to support dose optimization of iberdomide (IBER) as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial
Clinical Lymphoma Myeloma & Leukemia·2022· 2 cited
OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2022· 3 cited
Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients
eJHaem·2022· 2 citedOpen Access
P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL
HemaSphere·2022· 2 citedOpen Access
P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
HemaSphere·2022· 7 citedOpen Access
Model-Based Meta-analysis for the Population Pharmacokinetics of Iberdomide and Its Major Active Metabolite in Healthy Subjects and Subjects with Relapse and Refractory Multiple Myeloma
2022
page 1 of 4Next →

Frequent Co-authors

Katja Weisel(25), Meletios Α. Dimopoulos(24), Paul G. Richardson(23), Philippe Moreau(18), Albert Oriol(17), Mohamed H. Zaki(17), Enrique M. Ocio(14), Lars Sternås(14), Michèle Cavo(12), Sagar Lonial(12), Antonio Palumbo(11), Paolo Corradini(11), Michael Amatangelo(11), Michel Delforge(10), Pieter Sonneveld(9), Tsvetan Biyukov(9), Niels W.C.J. van de Donk(9), Darrell White(8), Mathew Simcock(8), Rakesh Popat(8)